Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

response to lapatinib

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Clinical data analysis reveals that the expression of the EphB4 receptor tyrosine kinase is significantly elevated in HER2… Expand
2018
2018
  • M. Fakih
  • The oncologist
  • 2018
  • Corpus ID: 4852857
Human epidermal growth factor 2 (HER2) amplification represents a distinct molecular subgroup of colorectal cancers that is… Expand
2015
2015
  • Trevor Dennie
  • Case reports in oncological medicine
  • 2015
  • Corpus ID: 17875618
Carcinoma of the lacrimal gland is a rare malignancy, limiting opportunities to develop new therapeutic regimens through clinical… Expand
2013
2013
Lapatinib, a small molecule tyrosine kinase inhibitor is currently used in the treatment of HER2-positive breast cancer. The aim… Expand
  • figure 1
  • figure 2
  • table 1
  • table I
  • figure 3
2011
2011
HER2-directed therapy has become an important agent in the treatment of metastatic breast cancer, and has altered the natural… Expand
2010
2010
We have read with great interest the article by Downey et al. on chromosome 17 polysomy without HER2 amplification and prediction… Expand
2009
2009
Background: Lapatinib (L) is a potent and selective dual inhibitor of EGFR and HER2. In HER2 positive metastatic breast cancer… Expand